Menu
Search
|

Menu

Close
X

Xenetic Biosciences Inc XBIO.OQ (NASDAQ Stock Exchange Capital Market)

2.46 USD
+0.08 (+3.36%)
As of Oct 12
chart
Previous Close 2.38
Open 2.44
Volume 1,333
3m Avg Volume 127,840
Today’s High 2.50
Today’s Low 2.44
52 Week High 8.94
52 Week Low 1.45
Shares Outstanding (mil) 8.72
Market Capitalization (mil) 25.89
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
8
FY16
3
FY15
0
EPS (USD)
FY18
-0.441
FY17
-0.421
FY16
-7.706
FY15
-2.936
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.75
Price to Sales (TTM)
vs sector
8.63
5.74
Price to Book (MRQ)
vs sector
2.25
5.00
Price to Cash Flow (TTM)
vs sector
--
23.28
Total Debt to Equity (MRQ)
vs sector
0.00
16.89
LT Debt to Equity (MRQ)
vs sector
0.00
12.55
Return on Investment (TTM)
vs sector
-72.68
14.60
Return on Equity (TTM)
vs sector
-141.57
16.33

EXECUTIVE LEADERSHIP

Jeffrey Eisenberg
Chief Executive Officer, Chief Operating Officer, Director, Since 2017
Salary: --
Bonus: --
James Parslow
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer, Since 2017
Salary: --
Bonus: --
Curtis Lockshin
Chief Scientific Officer, Since 2017
Salary: --
Bonus: --
Colin Hill
Treasurer, Secretary, Director, Since 2017
Salary: $253,133.00
Bonus: --
Timothy Cote
Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

99 Hayden Ave Ste 230
LEXINGTON   MA   02421-7998

Phone: +1781.7787720

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on discovery, research and development of biologic drugs and novel oncology therapeutics. The Company’s lead investigational product candidate is oncology therapeutic XBIO-101, which is used for the treatment of progestin - resistant endometrial cancer. The Company is currently conducting a Phase 2 trial for XBIO-101. The Company’s lead proprietary technology is PolyXen, which enables platform technology that can be applied to protein or peptide therapeutics using the natural polymer polysialic acid. The Company’s technology includes XBIO-101, PolyXen, OncoHist, ErepoXen and ImuXen. ErepoXen or polysialylated erythropoietin is an internal drug candidate which uses the company’s PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients.

SPONSORED STORIES